vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and MIND CTI LTD (MNDO). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $4.9M, roughly 1.9× MIND CTI LTD). MIND CTI LTD runs the higher net margin — 19.4% vs -265.9%, a 285.3% gap on every dollar of revenue. Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $4.0M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
MIND CTI Ltd. is a global provider of billing and customer care solutions and messaging services for voice, data, video and content services. Headquartered in Yokneam, Israel; the company also has offices in the United States of America, Iaşi in Romania and in Germany.
CLLS vs MNDO — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $4.9M |
| Net Profit | $-25.3M | $950.0K |
| Gross Margin | — | 55.4% |
| Operating Margin | -181.1% | 16.5% |
| Net Margin | -265.9% | 19.4% |
| Revenue YoY | 375.0% | — |
| Net Profit YoY | -51.9% | — |
| EPS (diluted) | $-0.28 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.9M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | — | $11.0M | ||
| Q4 24 | — | $5.2M | ||
| Q3 24 | — | $16.0M | ||
| Q2 24 | $9.5M | $10.7M | ||
| Q4 23 | — | $5.6M | ||
| Q3 23 | $1.6M | $16.2M |
| Q4 25 | — | $950.0K | ||
| Q3 25 | — | $3.4M | ||
| Q2 25 | — | $2.5M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | $-25.3M | $2.5M | ||
| Q4 23 | — | $1.4M | ||
| Q3 23 | $-17.5M | $4.0M |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 48.3% | ||
| Q2 25 | — | 50.6% | ||
| Q4 24 | — | 55.6% | ||
| Q3 24 | — | 50.6% | ||
| Q2 24 | — | 50.4% | ||
| Q4 23 | — | 49.5% | ||
| Q3 23 | — | 53.9% |
| Q4 25 | — | 16.5% | ||
| Q3 25 | — | 18.8% | ||
| Q2 25 | — | 21.0% | ||
| Q4 24 | — | 25.4% | ||
| Q3 24 | — | 22.5% | ||
| Q2 24 | -181.1% | 22.2% | ||
| Q4 23 | — | 20.6% | ||
| Q3 23 | -1258.1% | 26.7% |
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | 22.3% | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | -265.9% | 23.1% | ||
| Q4 23 | — | 25.6% | ||
| Q3 23 | -1064.1% | 24.8% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.16 | ||
| Q2 25 | — | $0.12 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.18 | ||
| Q2 24 | $-0.28 | $0.12 | ||
| Q4 23 | — | $0.06 | ||
| Q3 23 | $-0.31 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $8.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $23.0M |
| Total Assets | $407.1M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.3M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | — | $4.5M | ||
| Q4 24 | — | $4.6M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | $149.0M | $3.0M | ||
| Q4 23 | — | $16.4M | ||
| Q3 23 | — | $5.3M |
| Q4 25 | — | $23.0M | ||
| Q3 25 | — | $24.3M | ||
| Q2 25 | — | $24.3M | ||
| Q4 24 | — | $24.3M | ||
| Q3 24 | — | $24.5M | ||
| Q2 24 | $148.6M | $24.5M | ||
| Q4 23 | — | $24.5M | ||
| Q3 23 | $76.1M | $23.8M |
| Q4 25 | — | $30.2M | ||
| Q3 25 | — | $30.7M | ||
| Q2 25 | — | $30.7M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $31.6M | ||
| Q2 24 | $407.1M | $31.6M | ||
| Q4 23 | — | $31.6M | ||
| Q3 23 | $209.7M | $31.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $4.0M |
| Free Cash FlowOCF − Capex | $27.6M | $4.0M |
| FCF MarginFCF / Revenue | 290.5% | 81.0% |
| Capex IntensityCapex / Revenue | 13.2% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 4.20× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | — | $2.9M | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | $28.9M | $2.4M | ||
| Q4 23 | — | $4.1M | ||
| Q3 23 | — | $3.1M |
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | — | $2.9M | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | $27.6M | $2.4M | ||
| Q4 23 | — | $4.0M | ||
| Q3 23 | — | $3.0M |
| Q4 25 | — | 81.0% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | — | 25.8% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | 290.5% | 22.1% | ||
| Q4 23 | — | 72.0% | ||
| Q3 23 | — | 18.6% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 13.2% | 0.4% | ||
| Q4 23 | — | 1.1% | ||
| Q3 23 | — | 0.7% |
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 1.16× | ||
| Q4 24 | — | 3.32× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.97× | ||
| Q4 23 | — | 2.86× | ||
| Q3 23 | — | 0.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
